Similar Papers

Paper Title
Journal
Date
Author
LMO2 Facilitates Synthetic Lethality after PARP Inhibition (PARPi) in Diffuse Large B-Cell Lymphoma (DLBCL)
Ramiro E Verdun ... Izidore S Lossos
Blood | VOL. 132
Ramiro E Verdun, et. al.Ramiro E Verdun ... Izidore S Lossos
29 Nov 2018
A few good genes
Andrew J Gentles ... Ash A Alizadeh
Cell Cycle | VOL. 10
Andrew J Gentles, et. al.Andrew J Gentles ... Ash A Alizadeh
01 Nov 2011
Novel Role of LMO2 in DNA Repair Control in Diffuse Large B Cell Lymphoma
Salma Parvin ... Izidore S Lossos
Blood | VOL. 128
Salma Parvin, et. al.Salma Parvin ... Izidore S Lossos
02 Dec 2016
Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment
Ash A Alizadeh ... Ronald Levy
Blood | VOL. 116
Ash A Alizadeh, et. al.Ash A Alizadeh ... Ronald Levy
19 Nov 2010
View more papers

More From: Blood

Paper Title
Journal
Date
Author
TTP: a disorder for all physicians.
James N George
Blood | VOL. 146
James N GeorgeJames N George
10 Jul 2025
Redefining risk stratification in pLCH.
Jithma P Abeykoon ... W Oliver Tobin
Blood | VOL. 146
Jithma P Abeykoon, et. al.Jithma P Abeykoon ... W Oliver Tobin
10 Jul 2025
Beware the zombie enzyme.
David Dominguez-Sola
Blood | VOL. 146
David Dominguez-SolaDavid Dominguez-Sola
10 Jul 2025
A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22alt case.
Muna Al Jabri ... Ali Sakhdari
Blood | VOL. 146
Muna Al Jabri, et. al.Muna Al Jabri ... Ali Sakhdari
10 Jul 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.